ETHZilla Corporation Common Stock (ATNF) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Building 4
Palo Alto, CA 94306
United States of America (the)
Phone
650 507 0669
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
June 27, 2017
| Name | Title | Pay | Year Born |
| Lloyd Blair Jordan | Chief Executive Officer & Director | 211,982 | 1970 |
| Lawrence Steinman | Co-Founder & Director | 30,000 | 1948 |
| Sir Marc Feldman | Co-Founder | 130,062 | 1945 |
| Eric R. Van Lent | CAO, Principal Accounting & Financial Officer | 0 | 1983 |
| Jagdeep Nanchahal | Co-Founder & Chairman of Clinical Advisory Board | 0 | N/A |
1180 Life Sciences Corp. is a biotechnology firm currently in the clinical trial phase, dedicated to creating treatments for pressing medical challenges including chronic pain, inflammation, fibrosis, and other related inflammatory conditions. The company's therapeutic pipeline is supported by three primary development platforms: An anti-tumor necrosis factor (anti-TNF) and fibrosis platform is progressing through Phase IIb clinical trials, specifically targeting fibrosis and anti-TNF pathways. A Synthetic Cannabidiol (CBD) Analogs platform, featuring laboratory-created derivatives of CBD, is currently in preclinical development. An a7nAChR platform, which functions as an immune suppressive agent by focusing on the alpha 7 nicotinic acetylcholine receptor, is also undergoing preclinical evaluation. Established in 2016, 1180 Life Sciences Corp. is based in Palo Alto, California.